Silvia Escribano Serrat, MD

Visiting Investigator
The Precision Cellular Therapy Laboratory
Publications
Jobs
Members

Silvia Escribano Serrat, MD

Visiting Investigator
Share
Share

Silvia Escribano Serrat is a physician-scientist specializing in hematology working as a research fellow in the Shouval Lab. After graduating medical school at Universidad Autónoma de Madrid, Silvia completed her training in hematology and hemotherapy at Hospital Clínico San Carlos, where she was an active physician-scientist in the molecular biology laboratory. Between 2019-2024 she completed two Master‘s Degrees (Clinical Medicine at UCJC and Infectious Diseases and Antimicrobial Treatment at CEU), and obtained a specialist certificate at CAR-T cell therapy at Universitat de Vàlencia. During 2024 and 2025, Silvia worked as a physician and researcher at Hospital Clínic and IDIBAPS (Barcelona), first, in the clinical hematological diagnostic, and afterwards, in the immunotherapy laboratory developing several projects related to genomics, spectral flow cytometry and CAR-T. Throughout this period, she collaborated in the design and creation of a quality management system for the decentralized production of CAR-T cell therapies at Hospital Clínic, and contributed as an external consultant – clinical advisor in the development of clinical trials with academic CAR-T at Gyala Therapeutics (Barcelona). These background led her to join the Shouval Lab with the aim of deepening the knowledge of genomics and epigenomics in CAR-T cell therapies. 

Funding

FUNDAME grants – Alfonso Martín Escudero Foundation.

Grants/Awards/Highlights:

  • Best oral presentation at the Spanish Hematology and Hemotherapy National Congress – SCHH, Catalan Society of Hematology and Hemotherapy (2025).
  • XUEC – Network of Expert Clinical Units in Minor Non-Oncologic Hematologic Diseases. Hemostasis Disorders. Generalitat de Catalunya (2024).
  • Resident Medical Intern (MIR) Excellence Award – AMHH, Madrid Association of Hematology and Hemotherapy (2024).

Publications

Escribano-Serrat S, Pedraza A, Suárez-Lledó M, Charry P, De Moner B, Martinez-Sanchez J, Ramos A, Ventosa-Capell H, Moreno C, Guardia L, Monge-Escartín I, Riu G, Carcelero E, Cid J, Lozano M, Gómez P, García E, Martín L, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ, Díaz-Ricart M. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation. Bone Marrow Transplant. 2024 Oct;59(10):1466-1476. doi: 10.1038/s41409-024-02388-y.

Escribano-Serrat S, Rodríguez-Lobato LG, Suárez-Lledó M, Pedraza A, Charry P, Cid J, Lozano M, Esteve J, Rosiñol L, Fernández-Avilés F, Carreras E, Díaz-Ricart M, Martínez C, Rovira M, Salas MQ. Improving the EASIX’ predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Jul;59(7):1022-1024. doi: 10.1038/s41409-024-02267-6. 

Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L; Grupo Español de Leucemia Mieloide Crónica (GELMC). e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. J Clin Med. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779.

Palomo M, Moreno-Castaño AB, Salas MQ, Escribano-Serrat S, Rovira M, Guillen-Olmos E, Fernandez S, Ventosa-Capell H, Youssef L, Crispi F, Nomdedeu M, Martinez-Sanchez J, De Moner B, Diaz-Ricart M. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications. Front Med (Lausanne). 2023 Nov 14;10:1285898. doi: 10.3389/fmed.2023.1285898. 

Pedraza A, Salas MQ, Rodríguez-Lobato LG, Escribano-Serrat S, Suárez-Lledo M, Martínez-Cebrian N, Solano MT, Arcarons J, Rosiñol L, Gutiérrez-García G, Fernández-Avilés F, Moreno-Castaño AB, Molina P, Pino M, Carreras E, Díaz-Ricart M, Rovira M, Palomo M, Martínez C. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation. Transplant Cell Ther. 2024 Feb;30(2):187.e1-187.e12. doi: 10.1016/j.jtct.2023.11.016. 

Escribano-Serrat S, Rodríguez-Lobato LG, Charry P, Martínez-Cibrian N, Suárez-Lledó M, Rivero A, Moreno-Castaño AB, Solano MT, Arcarons J, Nomdedeu M, Cid J, Lozano M, Pedraza A, Rosiñol L, Esteve J, Urbano-Ispizua Á, Palomo M, Fernández-Avilés F, Martínez C, Díaz-Ricart M, Carreras E, Rovira M, Salas MQ. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Cytotherapy. 2024 Jan;26(1):73-80. doi: 10.1016/j.jcyt.2023.10.008.

Sanchez-Escamilla M, Flynn J, Devlin S, Maloy M, Fatmi SA, Tomas AA, Escribano-Serrat S, Ponce D, Sauter CS, Giralt SA, Scordo M, Perales MA. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023 May;58(5):498-505. doi: 10.1038/s41409-023-01922-8. 

Amich I, Anguita E, Escribano-Serrat S, Alvarez C, Rodríguez-Muñoz D, García V, Bello R, Peña-Pedrosa JA, Martínez-Micaelo N, Amigó N, Ortiz P, Torrejón MJ, Boscá L, Martín-Sánchez J, Aranda A, Alemany S. Free triiodothyronine levels and age influences the metabolic profile and COVID-19 severity parameters in euthyroid and levothyroxine-treated patients. Front Endocrinol (Lausanne). 2022 Nov 9;13:1025032. doi: 10.3389/fendo.2022.1025032. 

View a full listing of Silvia Escribano Serrat’s journal articles.